Advances in the pharmacological and neurological treatment of patients with multiple sclerosis

Shalini Bansil, Raymond Troiano, Peter C. Dowling, Christine Rohowsky-Kochan, Stuart D. Cook, Susan Barbieri-Berger

Research output: Contribution to journalArticlepeer-review

Abstract

Multiple sclerosis (MS) is an acquired inflammatory demyelinating disease of the central nervous system (CNS) believed to be of autoimmune pathogenesis. Progressive MS is a common cause of disability in young adults in the United States. Although several immunomodulating therapies have been tested in clinical and animal studies, there is no known treatment that prevents further progression and disability. Current research efforts are being focused on the development of novel, safe immunospecific treatments. Until such therapies become available, a major component of patient management should be to relieve symptoms, prevent complications, and maximize function in activities of daily living. A team approach involving health care professionals of various specialties is ideal for the management of patients with progressive MS.

Original languageEnglish (US)
Pages (from-to)1-8
Number of pages8
JournalNeuroRehabilitation
Volume3
Issue number4
DOIs
StatePublished - 1993

All Science Journal Classification (ASJC) codes

  • Physical Therapy, Sports Therapy and Rehabilitation
  • Rehabilitation
  • Clinical Neurology

Fingerprint Dive into the research topics of 'Advances in the pharmacological and neurological treatment of patients with multiple sclerosis'. Together they form a unique fingerprint.

Cite this